What Researchers Did
Researchers conducted a randomised, single-center, placebo-controlled clinical trial with 119 patients to evaluate the effects of hyperbaric oxygen therapy on chronic wounds and its correlation with CD34+ endothelial progenitor cells.
What They Found
The hyperbaric oxygen therapy group showed a significantly greater wound size decrease of 62.7% compared to 34.4% in the control group (P < 0.05). Additionally, peripheral CD34+ endothelial progenitor cells significantly increased from 0.24% before treatment to 1.75% after 20 sessions of hyperbaric oxygen therapy (P < 0.05).
What This Means for Canadian Patients
Hyperbaric oxygen therapy may offer a beneficial treatment option for Canadian patients suffering from chronic lower extremity wounds, potentially accelerating healing. This therapy could improve wound closure rates and promote the regeneration of endothelial progenitor cells, which are crucial for tissue repair.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A key limitation of this study is its single-center design, which may limit the generalizability of the findings.